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review and meta-analysis
Background Diabetic retinopathy (DR), the primary retinal vascular complica-
tion of diabetes mellitus (DM), is a leading cause of vision impairment and blind-
ness in working-age population globally. Despite mounting concerns about the 
emergence of DM as a major public health problem in the largest developing 
country, China, much remains to be understood about the epidemiology of DR. 
We aimed to investigate the prevalence of and risk factors for DR, and estimate 
the burden of DR in China in 2010.
Methods China National Knowledge Infrastructure (CNKI), Wanfang, Chinese 
Biomedicine Literature Database (CBM-SinoMed), PubMed, Embase and Med-
line were searched for studies that reported the prevalence of and risk factors 
for DR in Chinese population between 1990 and 2017. A random-effects me-
ta-analysis model was adopted to pool the overall prevalence of DR. Variations 
in the prevalence of DR in different age groups, DM duration groups and set-
tings were assessed by subgroup meta-analysis and meta-regression. Odds ratios 
(ORs) of major risk factors were pooled using random-effects meta-analysis. The 
number of people with DR in 2010 was estimated by multiplying the age-spe-
cific prevalence of DR in people with DM with the corresponding number of 
people with DM in China. Finally, the national number of people with DR was 
distributed into six geographic regions using a risk factor-based model.
Results A total of 31 studies provided information on the prevalence of DR and 
21 explored potential risk factors for DR. The pooled prevalence of any DR, 
nonproliferative DR (NPDR) and proliferative DR (PDR) was 1.14% (95% 
CI = 0.80-1.52), 0.90% (95% CI = 0.56-1.31) and 0.07% (95% CI = 0.02-0.14) 
in general population; In people with DM, the pooled prevalence rates were 
18.45% (95% CI = 14.77-22.43), 15.06% (95% CI = 11.59-18.88) and 0.99% 
(95% CI = 0.40-1.80) for any DR, NPDR and PDR, respectively. The prevalence 
of any DR in DM patients peaked between 60 and 69 years of age, and increased 
steeply with the duration of DM. DM patients residing in rural China were at a 
higher risk to have DR than those in urban areas. In addition, insulin treatment, 
elevated FBG level and higher HbA1c concentration were confirmed to be as-
sociated with a higher prevalence of DR in people with DM, with meta-ORs of 
1.99 (95% CI = 1.34-2.95), 1.33 (95% CI = 1.12-1.59) and 1.15 (95% CI = 1.09-
1.20) respectively. In 2010, a total of 13.16 million (95% CI = 8.95-18.00) Chi-
nese aged 45 years and above were living with DR, among whom the most were 
in South Central China and the least were in Northwest China.
Conclusions DR has become a serious public health problem in China. Opti-
mal screening of and interventions on DR should be implemented. Improved 
epidemiological studies on DR are still required.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Diabetic retinopathy (DR), the primary retinal vascular complication of diabetes mellitus (DM), is a leading 
cause of vision impairment and blindness in the working-age population [1-4]. In the early course of the dis-
ease, DR is generally asymptomatic. If left untreated, DR can seriously impair vision, and eventually progress 
to blindness [1,3]. Apart from its devastating visual effects that might lead to reduced mobility, depression 
and lower quality of life, DR is also associated with a higher risk of systemic vascular complications, impos-
ing a noteworthy burden on individuals, households, communities and societies [5-7]. DR is a progressive 
disease that can be broadly divided into two stages according to its severity: nonproliferative and proliferative. 
Nonproliferative DR (NPDR) is characterized by microaneurysms, cotton-wool spots, intraretinal microvas-
cular abnormalities, hard exudates and venous beading, whereas proliferative DR (PDR) is hallmarked by 
neovascularization of the optic disc or elsewhere, pre-retinal and vitreous haemorrhage [1,8]. Taken individ-
ually, PDR is less common but more sight-threatening than NPDR [1-3,8,9].
Although available diagnostic and therapeutic advancements, such as optimum management of DM and ear-
ly detection of DR, can substantially reduce the risk of visual deterioration, DR remains an important cause 
of visual impairment and blindness globally [10-16]. In 2010, 3.7 million people were visually impaired and 
0.8 million were blind because of DR, accounting for 1.9% of all visually impaired cases and 2.6% of all blind 
cases worldwide [13]. With DM having reached epidemic proportions worldwide, estimating the prevalence 
of DR in both the general population and those with DM is imperative for driving better health policy mak-
ing and improved programming [13,15]. By pooling data from 35 population-based studies across the world, 
the Global DR Study estimated that the prevalence of any DR, PDR and vision-threatening DR (severe reti-
nopathy and macular oedema) were 34.6%, 7.0% and 10.2% respectively among individuals with DM, trans-
lating to approximately 93 million people with any DR, 17 million with PDR and 28 million with vision-threat-
ening DR worldwide in 2010 [2]. Unless substantial improvements occur in the prevention and treatment of 
DR, the prevalence and burden of DR will continue to escalate as the global population ages and the epidem-
ic of DM expands [17-19]. In addition, evaluation of risk factors for DR is of special importance in optimal 
clinical management. Similar to other common complications of DM, DR is a sentinel indicator of the pro-
gression of DM, thus its prevalence, not surprisingly, associated with the duration and severity of DM [2,4,20]. 
In the Global DR Study, longer DM duration has been recognised as a key risk factor for DR in people with 
DM, as well as higher levels of haemoglobin A1c (HbA1c) and blood pressure. Moreover, individuals with 
type 1 DM (T1DM) are more likely to develop DR than those with type 2 DM (T2DM) [2,4].
Despite mounting concerns about the emergence of DM as a major public health problem in the largest de-
veloping country, China, epidemiological data on DR in Chinese population are still rather scarce or incon-
sistent [9,21-23]. Thus far, there is still no national population-based data on the prevalence and burden of 
DR in China, and the existing surveys on DR are restricted to local characteristics, study methodologies, as-
certainment and classification of DR, limiting direct comparisons between individual studies [22]. A system-
atic review and meta-analysis by Liu and colleagues, dating back to 2012, has provided the first overview of 
the DR prevalence in China. Based on 19 individual studies, their meta-analysis suggested that the pooled 
prevalence rates of any DR, NPDR and PDR in general Chinese population were 1.3%, 1.1%, and 0.1% and 
those in people with DM were 23.0%, 19.1%, and 2.8% respectively [22]. Thereafter, a growing body of ep-
idemiological data on DR has become available in China, yet virtually none of them has been systematically 
appraised, underscoring the need for an updated analysis [24,25]. Moreover, the effects of major risk factors 
for DR are still discrepant and inconclusive among the Chinese population, which need to be systematically 
evaluated in an evidence-based fashion.
To fill the gaps outlined above, we conducted a comprehensive systematic review, in both Chinese and En-
glish databases, to retrieve studies that reported the epidemiology of DR in China from 1990 onwards. Based 
on the existing evidence, we aimed to: (1) pool the overall prevalence of DR in both general Chinese popu-
lation and people with DM; (2) estimate the effects of demographic and geographic variables on the preva-
lence of DR in people with DM; (3) assess the major risk factors for DR in people with DM; and (4) quantify 
the national and subnational burden of DR in 2010.
METHODS
Systematic review
This systematic review and meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines and the Guidelines for Accurate and Transparent Health Esti-
mates Reporting (GATHER) statement [26,27].
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Search strategy
Three Chinese and three English electronic bibliographic databases, namely China National Knowledge 
Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database (CBM-SinoMed), PubMed, 
Embase, and Medline, were searched to locate all relevant publications that reported the epidemiology of 
DR in China. Our comprehensive search strategies combined terms of diabetic retinopathy, epidemiology 
(incidence, prevalence, morbidity, mortality, epidemiology) and China (China, Chinese, Hong Kong, Ma-
cau, Taiwan) using both controlled vocabularies (eg, Medical Subject Heading terms) and free text words. 
Search queries were optimised to fit the specific features of each database, and the full search strategies 
are detailed in Table S1 in Online Supplementary Document. To supplement the electronic database 
search, reference lists of eligible publications and related reviews were also scanned to identify other po-
tentially pertinent studies. The literature search was limited to studies published between January 1990 
and December 2017. No language restrictions were imposed on searches or search results.
Inclusion and exclusion criteria
To be included in the systematic review and meta-analysis, studies had to be population-based and re-
ported the prevalence of DR or risk factors for DR. Depending on how the study population was sought, 
the identified population-based studies can be classified into three categories: community-based, prima-
ry health care management (PHCM)-based and registry-based. Community-based studies derived their 
study sample from the general population (eg, cluster sampling of households), whereas PHCM-based 
and registry-based studies derived their study sample from all the primary care settings or primary care 
systems in a defined geographical area. Thus, both PHCM-based and registry-based studies attempted to 
capture all, or at least a random sample, of people with DM in a defined geographical area. For the pur-
pose of pooling prevalence rates of DR, the included studies must be community-based, and of particular 
note, include both newly detected and physician-diagnosed DM cases simultaneously (to avoid overesti-
mation); To assess the risk factors for DR in people with DM, the included studies could be communi-
ty-based, PHCM-based or registry-based, where DM cases could be either newly detected or physician-di-
agnosed, or both. To avoid suspected bias inherent to univariate analysis, the estimation of odds ratios 
(ORs) in studies that reported the risk factors for DR must be based on a multivariate study design.
Studies that were conducted in the T1DM group were excluded, whereas those focused on people with 
T2DM were retained. Studies that contained both T1DM and T2DM cases were not excluded if the pro-
portion of people with T1DM was small (<10%). For studies where the type of DM was not specified but 
all other criteria were fulfilled, it was assumed that those studies contained both T2DM cases and a small 
proportion of T1DM cases. Otherwise, the type of DM could be speculated by the age at diagnosis of DM 
(if available), where people diagnosed before 30 years were deemed as with T1DM and those after 30 
years were T2DM [2,28]. To be eligible for inclusion, studies must have undertaken fundus photography 
(FP) to ascertain DR and provided numerical estimates of DR prevalence. Reviews, commentaries and 
studies where the prevalence rates were calculated based on the number of eyes with DR rather than the 
number of affected individuals were excluded.
Study selection and data extraction
After deleting duplicate records within and between different bibliographic databases, the remaining ti-
tles and abstracts were independently reviewed by two authors (PS and JY) to identify potentially eligible 
articles that required a full appraisal. In cases of multiple publications from the same study or overlapping 
data, preference was given to the most recent one or the one with the most inclusive information. Con-
sensus was achieved for any discrepancies in study eligibility through discussion. With a predefined da-
ta-collection form, the following information was extracted from the included studies, where possible:
1)  Characteristics of the study: author(s), publication year, study year, study type (community-based, 
PHCM-based or registry-based), sampling method, study design (cross-sectional or cohort), study 
setting (urban, rural or mixed) and location, geographic region, DR assessment method and grad-
ing system;
2)  Characteristics of the sample (general population and people with DM): number of the sample, 
age (age range, mean or median age), gender (male, female or mixed), DM definition, DM classi-
fication (T1DM or T2DM, newly detected or physician-diagnosed), and duration of DM;
3)  Prevalence data: the number of people with DR and the number of participants who had been 
tested for DR, by age, DM duration, gender, setting and DR subtype;
4)  Risk factor data: definition of risk factor, OR and corresponding confidence intervals (CIs).
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According to the definitions from National Bureau of Statistics of China, the geographic regions where 
the studies were carried out were classified into six categories: East China, North China, Northeast 
China, Northwest China, South Central China, and Southwest China (see Table 1) [29,30]. Missing 
values for the median year of study were imputed by subtracting three years (the average time-lag 
from investigation to publication in studies with available data) from their publication years, and this 
was done for six individual studies. In this study, we further classified DR as NPDR and PDR. There-
fore, relevant data were extracted from the included studies for different subtypes of DR respectively, 
wherever available.
Table 1. The six geographic regions in China
Region included pRovinces
North China Beijing Municipality, Hebei province, Inner Mongolia Autonomous Region, Shanxi province, Tianjin Municipality
Northeast China Heilongjiang province, Jilin province, Liaoning province
East China Anhui province, Fujian province, Jiangsu province, Jiangxi province, Shandong province, Shanghai Municipality, Zhejiang province
South Central China Guangdong province, Guangxi Zhuang Autonomous Region, Hainan province, Henan province, Hubei province, Hunan province
Southwest China Chongqing Municipality, Guizhou province, Sichuan province, Tibet Autonomous Region, Yunnan province
Northwest China Gansu province, Ningxia Hui Autonomous Region, Qinghai province, Shaanxi province, Xinjiang Uyghur Autonomous Region
Statistical analysis
Pooling prevalence of DR in China
The crude prevalence of DR was first computed for each study and then double-arcsine transformed by 
using the Freeman-Tukey method [31-33]. Heterogeneity among eligible studies was assessed with the 
Cochran’s Q statistic and I2 index (the proportion of total variability due to true between-study heteroge-
neity beyond chance) [34,35]. A p-value of less than 0.1 showed the presence of heterogeneity, and I2 
values of less than 25% corresponded to mild heterogeneity, of from 25% to 50% reflected moderate het-
erogeneity, and of greater than 50% represented high heterogeneity, respectively [34-36]. Because of the 
substantial heterogeneity noted between individual studies, a random-effects (DerSimonian and Laird 
method) meta-analysis was used to adjust for variability and pool the study-specific prevalence rates 
[32,36]. For each meta-analysis, a leave-one-out sensitivity analysis was developed to assess the robust-
ness of the pooled results. By removing one study at a time to run the meta-analysis without it, the sen-
sitivity analysis could test whether single studies had a disproportionally excessive influence on the pooled 
results [37]. Publication bias was checked by visual inspection of funnel plots, and tested for significance 
with Egger’s regression test for funnel plot asymmetry and Begg’s rank correlation test [38-40]. The prev-
alence rates of any DR, NPDR and PDR in both general population and people with DM were pooled with 
this approach respectively.
Subgroup meta-analysis and meta-regression of DR prevalence in people with DM
For the prevalence of any DR in people with DM, potential sources of heterogeneity were investigated us-
ing subgroup meta-analysis and meta-regression. In subgroup meta-analysis, the prevalence of any DR 
was estimated for different age groups and DM duration groups. This was done because age- and DM du-
ration-specific prevalence of any DR in people with DM was universally provided by the included stud-
ies. Moreover, the individual associations between prevalence of any DR and study-level variables were 
evaluated by univariable meta-regression using unrestricted maximum likelihood method. The prespec-
ified variables included gender (male vs female), setting (urban, rural and mixed), geographic region and 
study year. Because only a few variables were individually significant, a multivariable meta-regression was 
not subsequently performed.
Meta-analysis of risk factors for DR in people with DM
To investigate the risk factors for any DR in people with DM, a random-effects meta-analysis was em-
ployed a priori because of anticipated variation in study populations, geography and study design. As a 
rule, we only included risk factors that were investigated in at least three studies using multivariate de-
sign, and the definitions of the same risk factor should be similar across all included studies. Finally, 11 
factors (advanced age, male gender, DM duration, insulin treatment, fasting blood glucose [FBG], 2-hour 
postprandial blood glucose [2h-PBG], glycated haemoglobin A1c [HbA1c], total cholesterol [TC], tri-
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glyceride [TG], body mass index [BMI], systolic blood pressure [SBP]) met our criteria and were includ-
ed in meta-analysis.
Estimation of national and subnational burden of DR in 2010
At the final stage, the national number of cases with any DR (“any DR envelope”) was estimated by mul-
tiplying the age-specific prevalence of any DR in people with DM with the corresponding number of peo-
ple with DM in China. For this purpose, the 2011 national baseline survey of China Health and Retire-
ment Longitudinal Study (CHARLS), a nationally representative survey of Chinese people aged 45 years 
and older by using a four-stage, stratified, cluster sampling procedure, was selected to provide prevalence 
estimates of DM in China for the year 2010, and the Chinese population data were obtained from the 
United Nations Population Division (UNPD) [41]. The number of people with DM was estimated with 
the prevalence of DM and the corresponding population size. The study design and implement of CHARLS 
have been published previously and the procedures for deriving the prevalence of DM are outlined in Ta-
ble S2 and Figures S1-S2 in Online Supplementary Document [42,43]. Then the national number of 
people with any DR (“any DR envelope”) was distributed into six geographical regions in China (East 
China, North China, Northeast China, Northwest China, South Central China, Southwest China) by tak-
ing the effects of major risk factors on the prevalence of any DR in those regions [44,45]. Four statistical-
ly significant risk factors (advanced age, rural setting, elevated FBG level and higher HbA1c concentra-
tion) were chosen because they were all objective indicators. DM duration and insulin treatment, although 
being significantly associated with the prevalence of any DR, were not selected because they were highly 
subject to the diagnosis and treatment of DM, socioeconomic circumstances or geography, and therefore 
might introduce bias in our estimation of DR burden at the subnational level.
A two-sided p-value of less than 0.05 indicated statistical significance except for the Q statistics, in which 
a significance level of less than 0.1 was specified. All statistical analyses were done with R version 3.3.0 
(R Foundation for Statistical Computing, Vienna, Austria) and STATA version 14.0 (STATA Corporation, 
College Station, TX, USA). All maps were drawn by ArcMap version 10.1 (Environmental Systems Re-
search Institute, Redlands, CA, 
USA) using the China base map 
obtained from the Global Adminis-
trative Areas (GADM) database 
(GADM, 2015, version 2.0; www.
gadm.org).
RESULTS
Summary of systematic 
review
The initial search strategy yielded 
9982 records. After removal of 
4644 duplicates, a total of 5338 re-
cords were reviewed for relevance 
by titles and abstracts, of which 
1147 were assessed in full-text 
form. Finally, 41 articles met eligi-
bility criteria and were included in 
the systematic review. Of these, 31 
studies provided information on 
the prevalence of DR and 21 ex-
plored potential risk factors for DR. 
The process of study selection is 
summarised in Figure 1 according 
to the PRISMA guidelines. A full 
list of the included studies is shown 
in Table S3 in Online Supplemen-
tary Document.
Figure 1. Systematic review flow diagram of studies on the prevalence of and risk factors for 
diabetic retinopathy (DR) in China. PHCM - Primary Health Care Management; *Reason 1 
– Studies that were not community-based, PHCM-based or registry-based; *Reason 2 – Stud-
ies that were not based in China; *Reason 3 – Articles with no numerical prevalence measure 
of DR or didn’t report risk factor for DR in people with diabetes mellitus (DM); *Reason 4 – 
Studies with no clear assessment methods or grading systems of DR; *Reason 5 – Studies that 
were specifically conducted in people with unrepresentative characteristics (hypertensive pa-
tients, people with reduced vision, etc.); *Reason 6 – Multiple publications of the same study; 
*Reason 7 – Studies that didn’t include both newly detected and diagnosed DM cases.
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All included studies were cross-sectional in design and 
assessed DR by using FP. Table 2 summarises the main 
characteristics of all included studies, and Table S4 in 
Online Supplementary Document lists the detailed 
characteristics of every study. For the 31 studies that 
reported the prevalence of DR and the 21 studies on 
risk factors for DR, the majority were published after 
2010, implying the necessity for an updated analysis 
of the epidemiology of DR in China. The studies on 
the prevalence of DR were all community-based in-
vestigations, covering all the six geographic regions 
across China (see Figure 2). For those on risk factors 
for DR, more than half were community-based (71%, 
n = 15), whereas more than one third were conducted 
in East China (38%, n = 8). There were no studies from 
Northwest China on which to base estimates of risk 
factors for DR (see Figure 2).
Pooled prevalence of DR in China 
during 1990 and 2017
By using random-effects meta-analysis, the pooled 
prevalence of any DR in general Chinese population 
was 1.14% (95% CI = 0.80-1.52), and that in people 
with DM was 18.45% (95% CI = 14.77-22.43) (Figure 
3). According to the leave-one-out sensitivity analysis 
(Figure S3 in Online Supplementary Document), 
the pooled prevalence of any DR in general population 
varied from 1.08% (95% CI = 0.76-1.46) to 1.19% 
(95% CI = 0.86-1.58), and that in people with DM 
ranged from 17.67% (95% CI = 14.12-21.53) to 
19.01% (95% CI = 15.38-22.94), no single study sig-
nificantly influenced the overall pooled prevalence in 
the meta-analysis. No publication bias was evident 
based on the visual evaluation of the funnel plot, 
Egger’s test and Begg’s test (Figure S4 in Online Sup-
plementary Document).
For NPDR, the pooled prevalence in general popula-
tion was 0.90% (95% CI = 0.56-1.31), and that in peo-
Table 2. Main characteristics of the included studies on the prevalence 
of and risk factors for diabetic retinopathy in China*
chaRacteRistics of study
numbeR of studies (%)
Studies on DR prevalence 
(n = 31)
Studies on risk 
factors for DR (n = 21)
Year published:
1990-1999 4 (12.9) 1 (4.8)
2000-2009 7 (22.6) 5 (23.8)
2010-2017 20 (64.5) 15 (71.4)
Study design:
Community-based 31 (100.0) 15 (71.4)
PHCM-based 0 (0.0) 5 (23.8)
Registry-based 0 (0.0) 1 (4.8)
Setting:
Urban 12 (38.7) 15 (71.4)
Rural 7 (22.6) 3 (14.3)
Mixed 12 (38.7) 3 (14.3)
Gender:
Mixed 13 (41.9) 3 (14.3)
Both 18 (58.1) 18 (85.7)
Sample size of DM:
≤200 6 (19.4) 2 (9.5)
201-500 12 (38.7) 5 (23.8)
501–1000 9 (29.0) 6 (28.6)
>1000 4 (12.9) 8 (38.1)
Grading system:
ICDRDSS 12 (38.7) 11 (52.4)
ETDRS 6 (19.4) 7 (33.3)
NOFDG 3 (9.7) 1 (4.8)
NCOFD 9 (29.0) 2 (9.5)
CBM 1 (3.2) 0 (0.0)
Geographic regions:
North China 11 (35.5) 7 (33.3)
Northeast China 5 (16.1) 3 (14.3)
East China 5 (16.1) 8 (38.1)
South Central China 4 (12.9) 2 (9.5)
Southwest China 1 (3.2) 1 (4.8)
Northwest China 5 (16.1) 0 (0.0)
DR – diabetic retinopathy, DM – diabetes mellitus, PHCM – Primary Health Care 
Management, ICDRDSS – International Clinical Diabetic Retinopathy Disease 
Severity Scale, ETDRS – Early Treatment of Diabetic Retinopathy Study, NOFDG 
– National Ocular Fundus Diseases Group, NCOFD – National Conference on 
Ocular Fundus Diseases, CBM – China Medical Board
*11 studies reported both prevalence of DR and risk factors for DR, therefore 
the sum of the number of studies exceeded 41.
Figure 2. Geographical distribution of included studies on prevalence of and risk factors for diabetic retinopathy (DR) in China.
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ple with DM was 15.06% (95% CI = 11.59-18.88) by use of random-effects meta-analysis (Figure 4). The 
leave-one-out sensitivity analysis suggested that no individual study significantly influenced the overall 
pooled prevalence in the meta-analysis (Figure S5 in Online Supplementary Document), where the 
pooled prevalence of NPDR in general population ranged from 0.79% (95% CI = 0.49-1.14) to 0.99% 
(95% CI = 0.63-1.42) and that in people with DM from 13.92% (95% CI = 11.20-16.87) to 15.85% (95% 
CI = 12.48-19.53). Among studies that reported the prevalence of NPDR in general population, potential 
publication bias was revealed by the asymmetrical shape of funnel plot, Egger’s test and Begg’s test, where-
as no publication bias was suggested for studies that reported the prevalence of NPDR in people with DM 
(Figure S6 in Online Supplementary Document).
Figure 3. Pooled prevalence of any diabetic retinopathy (DR) in general population and in people with DM by random-effects 
meta-analysis. There were 28 studies for synthesizing the prevalence of any DR in general population and 31 in people with DM.
Figure 4. Pooled prevalence of nonproliferative diabetic retinopathy (NPDR) in general population and in people with diabetes 
mellitus (DM) by random-effects meta-analysis. There were 14 studies for synthesizing the prevalence of NPDR in general population 
and 17 in people with DM.
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As shown in Figure 5, the pooled prevalence of PDR from random-effects meta-analysis was 0.07% (95% 
CI = 0.02-0.14) in general population and 0.99% (95% CI = 0.40-1.80) in people with DM. The subse-
quent sensitivity analysis showed that the pooled prevalence of PDR was not affected unduly by a single 
study, where the pooled prevalence rates ranged from 0.05% (95% CI = 0.01-0.10) to 0.08% (95% 
CI = 0.03-0.16) in general population, and from 0.76% (95% CI = 0.30-1.39) to 1.07% (95% CI = 0.43-
1.95) in people with DM (Figure S7 in Online Supplementary Document). For studies that reported 
the prevalence of PDR in general population, visual inspection of the funnel plot and Begg’s test demon-
strated some evidence of significant publication bias, which was not confirmed by the Egger’s test. No 
publication bias was detected in the meta-analysis of PDR prevalence in people with DM (Figure S8 in 
Online Supplementary Document).
Figure 5. Pooled prevalence of proliferative diabetic retinopathy (PDR) in general population and in people with diabetes mellitus 
(DM) by random-effects meta-analysis. There were 14 studies for synthesizing the prevalence of PDR in general population and 17 
in people with DM.
Subgroup meta-analysis and meta-
regression of DR prevalence in people 
with DM
The age-specific prevalence of any DR in people 
with DM was derived based on subgroup me-
ta-analysis (Figure 6). The following age categories 
were adopted: 30-39 years, 40-49 years, 50-59 
years, 60-69 years, 70-79 years and 80 years and 
older. Before the age of 70 years, the prevalence of 
any DR in people with DM kept rising from 12.55% 
(95% CI = 4.93-22.52) in adults aged 30-39 to 
20.44% (95% CI = 15.04-26.36) in those were 60-
69 years old. Then the prevalence of any DR in 
people with DM started to decrease, until 11.22% 
(95% CI = 2.57-23.12) in elderly aged 80 years and 
above. The detailed process of synthesizing the 
prevalence of any DR in people with DM in each 
age category can be found in Figure S9 in Online 
Supplementary Document.
By pooling the prevalence of any DR in strata of 
DM duration group, it was revealed that the prev-
alence of any DR in people with DM substantially 
increased with the duration of DM. Four different 
DM duration groups were used: 0-year (newly de-
Figure 6. Age-specific prevalence of any diabetic retinopathy (DR) in 
people with diabetes mellitus (DM) by random-effects meta-analysis. The 
numbers of individual studies contributing to the synthesis of prevalence 
in each age group are 4 (for 30-39 years), 10 (for 40-49 years), 15 (for 
50-59 years), 16 (for 60-69 years), 10 (for 70-79 years) and 9 (for 80-89 
years) respectively.
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tected), 1-4 years, 5-9 years and 10 years and lon-
ger. According to the subgroup meta-analysis (Fig-
ure 7), the DM duration-specific prevalence of any 
DR ranged from 9.00% (95% CI = 5.15-13.75) in 
people with newly detected DM to 55.52% (95% 
CI = 47.90-63.02) in those who had been diag-
nosed with DM for 10 years and longer. The pro-
cess of synthesizing the prevalence of any DR in 
each DM duration group is detailed in Figure S10 
in Online Supplementary Document.
According to the univariable meta-regression (Ta-
ble 3), DM patients living in rural areas were more 
likely to have any DR than those in urban areas, 
with an OR of 1.22 (95% CI = 1.10-1.35). Howev-
er, no evidence of gender difference, geographical 
variation or a secular trend in the prevalence of any 
DR in individuals with DM was observed.
Synthesized effect size of risk factors 
for DR in people with DM
A total of 21 studies described the risk factors for 
any DR in people with DM by multivariate logistic 
regression (Table S5 in Online Supplementary 
Document). Risk factors for any DR were reported 
in various ways, among which 11 were with con-
sistent definitions and sufficient information, and 
therefore were included in evidence synthesis (Ta-
ble 4). Advanced age was found to be negatively 
associated with any DR, which was partly in line 
with our estimates on the age-specific prevalence 
of any DR, where the prevalence of any DR started 
to decrease from 70 years onwards. In accordance 
with the estimated DM duration-specific preva-
lence of any DR in subgroup meta-analysis, longer 
DM duration was additionally recognised as a sig-
nificant risk factor for any DR. DM patients receiv-
ing insulin treatment were almost two times more 
likely to have any DR than those who were not 
treated by insulin (OR 1.99 [95% CI = 1.34-2.95]). 
Moreover, elevated FBG level and higher HbA1c 
concentration were all identified as important risk 
factors for any DR, with ORs per unit increase of 
Figure 7. The prevalence of any diabetic retinopathy (DR) by diabetes 
mellitus (DM) duration group, using random-effects meta-analysis. The 
numbers of individual studies contributing to the synthesis of prevalence 
in each DM duration group are 13 (for newly diagnosed), 7 (for 1-4 
years), 8 (for 5-9 years) and 9 (for ≥10 years) respectively.
Table 3. Odds ratios for any diabetic retinopathy in terms of setting, 
geographic region and study year from univariable meta-regression 
models, with 95% confidence intervals
vaRiable numbeR of 
studies
oR (95% ci) z value p-value
Gender:*
Female
18
Reference Reference Reference
Male 0.98 (0.88-1.08) -0.47 0.639
Setting:
Urban 12 Reference Reference Reference
Rural 7 1.22 (1.10-1.35) 3.74 <0.001
Mixed 12 1.01 (0.93-1.10) 0.24 0.810
Geographic region:
North China 11 Reference Reference Reference
Northeast China 5 0.96 (0.82-1.13) -0.48 0.632
East China 5 0.99 (0.85-1.17) -0.07 0.946
South Central China 4 0.95 (0.80-1.13) -0.55 0.582
Southwest China 1 0.94 (0.69-1.28) -0.39 0.699
Northwest China 5 0.97 (0.82-1.15) -0.34 0.735
Study year (per decade) 31 1.01 (0.93-1.09) 0.22 0.826
*The effect of gender was estimated based on studies where gender-specific preva-
lence was available.
Table 4. Synthesized effect size of 11 risk factors for any diabetic retinopathy in people with diabetes mellitus
Risk factoR numbeR of studies oR (95% ci) z value p-value
Risk factor 1-Advanced age (per year increase) 4 0.96 (0.93-1.00) 2.26 0.024
Risk factor 2-Male 5 1.41 (0.88-2.27) 1.42 0.156
Risk factor 3-DM duration (per year increase) 12 1.09 (1.06-1.12) 5.93 <0.001
Risk factor 4-Insulin treatment 5 1.99 (1.34-2.95) 3.4 0.001
Risk factor 5-FBG (per mmol/L increase) 9 1.33 (1.12-1.59) 3.23 0.001
Risk factor 6-2h PBG (per mmol/L increase) 3 1.94 (0.81-4.65) 1.48 0.138
Risk factor 7-HbA1c (per % increase) 7 1.15 (1.09-1.20) 5.80 <0.001
Risk factor 8-TC (per mmol/L increase) 3 0.97 (0.78-1.20) 0.32 0.749
Risk factor 9-TG (per mmol/L increase) 3 1.66 (0.74-3.73) 1.24 0.216
Risk factor 10-BMI (per kg/m2 increase) 6 1.07 (0.94-1.21) 1.06 0.289
Risk factor 11-SBP (per mmHg increase) 5 1.03 (1.00-1.07) 1.96 0.05
OR – odds ratio, CI – confidence interval, DM – diabetes mellitus, FBG – fasting blood glucose, PBG – postprandial blood glucose, 
HbA1c – glycated haemoglobin A1c,TC – total cholesterol, TG – triglyceride, BMI – body mass index, SBP – systolic blood pressure
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1.33 (95% CI = 1.12-1.59) and 1.15 (95% CI = 1.09-1.20) respectively. Individual forest plots of meta-anal-
yses for each risk factor can be found in Table S6 in Online Supplementary Document.
National and subnational number of people with DR in 2010
According to the CHARLS 2011, the weighted prevalence of DM was 17.22% (95% CI = 15.57-19.00) in 
middle-aged and older Chinese in 2010 (see Table S7 in Online Supplementary Document for more 
details). By applying the age-specific prevalence of any DR in people with DM and the corresponding 
age-specific DM cases, the number of middle-aged and older Chinese with any DR was estimated to be 
13.16 million (95% CI = 8.95-18.00) in 2010, translating to an overall prevalence of 3.06% (95% CI = 2.08-
4.19) in general middle-aged and older Chinese and of 18.24% (95% CI = 12.41-24.95) in middle-aged 
and older Chinese with DM (Table 5). Based on the variations of population age structure, setting, mean 
FBG and mean HbA1c levels, the national DR cases were distributed into six geographic regions. As il-
lustrated in Table 5 and Figure 8, 
South Central China harboured the 
most DR cases (3.71 million [95% 
CI = 2.52-5.09]), while Northwest 
China had the least (0.87 million 
[95% CI = 0.60-1.18]). Regarding 
the prevalence of any DR at region-
al level, it was estimated that the 
prevalence of any DR in general 
middle-aged and older Chinese was 
the highest in North China (3.76% 
[95% CI = 2.56-5.12]) and the low-
est in Southwest China (2.55% 
[95% CI = 1.74-3.48]); For the prev-
alence of any DR in middle-aged 
and older Chinese with DM, it was 
the highest in Northwest China, 
while the lowest in East China 
(17.67% [95% CI = 11.97-24.24]).
Figure 8. Estimated regional number of middle-aged and older Chinese with any diabetic 
retinopathy (DR) and contributing age groups in 2010.
Table 5. Estimated prevalence and number of middle-aged and older Chinese with any diabetic retinopathy in 
China in 2010, by geographic region
Region pRevalence of any dR in geneRal 
people (%, 95% ci)
pRevalence of any dR in people with 
dm (%, 95% ci)
numbeR of people with dR 
(million, 95% ci)
North China 3.76 (2.56-5.12) 18.54 (12.66-25.28) 2.03 (1.39-2.77)
Northeast China 3.22 (2.20-4.39) 18.93 (12.94-25.81) 1.35 (0.92-1.84)
East China 2.74 (1.86-3.76) 17.67 (11.97-24.24) 3.63 (2.46-4.98)
South Central China 3.31 (2.25-4.54) 17.97 (12.19-24.63) 3.71 (2.52-5.09)
Southwest China 2.55 (1.74-3.48) 18.73 (12.76-25.59) 1.56 (1.07-2.14)
Northwest China 3.09 (2.12-4.20) 19.39 (13.30-26.35) 0.87 (0.60-1.18)
China 3.06 (2.08-4.19) 18.24 (12.41-24.95) 13.16 (8.95-18.00)
DR – diabetic retinopathy, DM – diabetes mellitus, CI – confidence interval
DISCUSSION
By combining all available epidemiological data on the prevalence of DR in China from 1990 onwards, 
we estimated that in general population, the pooled prevalence of any DR, NPDR and PDR was 1.14% 
(95% CI = 0.80-1.52), 0.90% (95% CI = 0.56-1.31) and 0.07% (95% CI = 0.02-0.14); In people with DM, 
the pooled prevalence rates were 18.45% (95% CI = 14.77-22.43), 15.06% (95% CI = 11.59-18.88) and 
0.99% (95% CI = 0.40-1.80) for any DR, NPDR and PDR, respectively. The prevalence of any DR in DM 
patients peaked between 60 and 69 years of age, and increased steeply with the duration of DM. DM pa-
tients residing in rural China were at a higher risk to have any DR than those in urban areas. In addition, 
insulin treatment, elevated FBG level and higher HbA1c concentration were confirmed to be associated 
with a higher prevalence of any DR in people with DM. In 2010, a total of 13.16 million (95% CI = 8.95-
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18.00) Chinese aged 45 years and above were living with any DR, among whom the most were in South 
Central China and the least were in Northwest China. Collectively, these data suggest a considerable bur-
den of DR in China.
To the best of our knowledge, this systematic review and meta-analysis provides a comprehensive esti-
mation of the prevalence, risk factors and burden of DR in China. Although this study is subsequent to 
the first synthesized analysis by Liu and colleagues, many new merits are highlighted [22]. The principal 
strengths of this study include a comprehensive search strategy in both Chinese and English databases 
and a dual review process, which increased our ability to capture all studies on DR epidemiology in Chi-
na. Ultimately, our estimation of DR prevalence was based on a total of 31 studies, which was more than 
1.5 times the number of studies included in the first systematic review on DR in China. Another import-
ant feature that distinguished our study with the previous systematic review by Liu and colleagues was 
that only community-based studies incorporating both newly detected and already diagnosed DM cases 
were included for the estimation of DR prevalence, therefore the representativeness of our estimates can 
be greatly guaranteed. Regarding risk factors for DR, only studies that provided estimates of OR using 
multivariate study designs were included, therefore community-based, PHCM-based and registry-based 
studies could all contribute, ensuring a sufficient power for conducting reliable synthesized assessments. 
Furthermore, the definitions of risk factors in included studies were similar, as well as in the CHARLS 
2011 [42,43]. Before pooling, an arcsine transformation was conducted to stabilise the variance of prev-
alence rates, which reduced the bias associated with small and large prevalence values on the pooled es-
timates to a large extent [32,33]. Although differences existed in the prevalence rates of DR across differ-
ent subgroups, our detailed assessment of any DR prevalence by age and DM duration group, and 
identification of risk factors for any DR could serve as a source of primary information and guide policy 
making and rational planning of health services, especially in areas where local investigations on the ep-
idemiology of DR are absent.
Before interpreting the findings, potential limitations of this systematic review and meta-analysis should 
be carefully considered. First, the pooled prevalence of NPDR and PDR in general population might have 
been affected by publication bias. Generally, publication bias arises because statistically significant results 
are more likely to be published than non-significant results, combining these studies for analysis could, 
therefore, introduce bias [40,46,47]. Unfortunately, we could not completely rule out publication bias 
because of the observational nature of our study. Second, there are inherent disadvantages in pooling 
prevalence form disparate studies. Due to the absence of stratified prevalence data for NPDR and PDR, 
we were not able to further explore sources of heterogeneity by subgroup meta-analysis and meta-regres-
sion for these two subtypes of DR. For any DR, sufficient data were available to pool the prevalence esti-
mates and no publication was detected. However, our subgroup analysis on the prevalence of any DR by 
age group and DM duration group was only based on a limited number of studies that provided corre-
spondingly stratified prevalence estimates. Third, only 11 risk factors with similar definitions across the 
included studies were systematically assessed, among which advanced age, longer DM duration, insulin 
treatment, elevated FBG level and higher HbA1c concentration were identified to be associated with a 
higher prevalence of any DR. However, because of the paucity of reported ORs, the effects of TC, TG and 
SBP should be further confirmed with new data coming in from future studies. In addition, previous stud-
ies have suggested that socioeconomic factors, including the availability and costs of DM management, 
were also likely to contribute to the disparities in DM severity and DR prevalence rates in different sub-
groups, but could not to be assessed in the current study [1,2,9]. Fourth, the number of DM cases in Chi-
na for generating the national and subnational burden of any DR was derived from the CHARLS 2011, 
which was nationally representative but only conducted in middle-aged and older population [42,43]. 
Therefore, the estimated number of people with any DR in this study was only for people aged 45 years 
and above. When distributing the national DR cases into the six geographic regions, we only took the ef-
fects of four objective indicators into account, namely, advanced age, rural setting, elevated FBG level and 
higher HbA1c concentration. Other subjective risk factors (eg, insulin treatment and DM duration) and 
potential factors that might be associated with the prevalence of DR were not included in our analysis of 
regional burden of DR in China, which might reduce the reliability of our estimation at the subnational 
level. Bearing those limitations in mind, the results presented in this study should be interpreted judi-
ciously.
In this study, significant heterogeneity was noted in pooling the prevalence rates of DR. The main sourc-
es of heterogeneity in the included studies pertained to the different characteristics of study population. 
After omitting each study at a time, the pooled prevalence of any DR was robust and consistent. The 
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pooled prevalence of any DR in Chinese people with DM was lower in our study than that in the global 
DR study (18.45% vs 25.08%) [2]. Given that the estimated prevalence of any DR in Chinese people with 
DM presented in the global DR study was based on studies that were conducted both within and outside 
China, any differences in exposure levels of risk factors might explain this discrepancy. Compared with 
the pooled prevalence of any DR in Chinese people with DM reported by Liu and colleagues, our study 
revealed a relatively lower prevalence rate (23.0% vs 18.45%) [22]. There are a number of possible rea-
sons for this difference. First, the improvement of primary health care management in China might have 
resulted in a lower incidence of DR in recent years. Second, more recent investigations might include 
more newly detected DM patients. The incidence of DM is higher than that of DR, resulting in a relative-
ly larger denominator for calculating the prevalence of DR. Most importantly, individual studies included 
in the systematic review and meta-analysis by Liu and colleagues were not solely focused on generally 
Chinese population, where both newly detected and diagnosed DM (self-reported physician diagnosed 
DM in some studies) cases should exist simultaneously. Two individual studies that were conducted in 
people with diagnosed DM were included in their final synthesis, the erroneous omission of people with 
newly detected or early-stage DM from the sample denominator would, therefore, lead to an overestima-
tion of DR prevalence [22]. Furthermore, a study included in their synthesized analysis was specifically 
conducted in a group of people with higher risk for pre-diabetes (eg, people with familial DM history, 
hypertension, overweight/obesity, dyslipidemia, cardiovascular disease /stroke or a gestational history of 
large babies [for women]) rather than in general population, which will also add further possibility of an 
overestimation [22,48].
In our analysis, the prevalence of any DR was found to peak between 60 and 69 years of age, which is in 
line with the age-specific prevalence estimates of DR among Americans [4,49]. In elderly with DM, the 
incidence of DR is relatively lower than that in younger people [9,50]. Given that DR is a marker for se-
vere DM and other life-threatening complications, a reduced survival rate has been observed in older 
people living with DR [51-55]. Therefore, this pattern of declining DR prevalence in elderly seems to be 
driven by the combination of reduced incidence and improved mortality. Unsurprisingly, the prevalence 
of DR is strongly associated with the duration of DM, which has been validated by both sub-group me-
ta-analysis and our meta-analysis on major risk factors for DR in this present study. This finding is con-
sistent with other previous investigations and synthesized analyses [2,55,56]. As revealed by our analysis, 
more than half of all patients with DM for 10 years and longer will develop some degree of DR, under-
scoring the importance of optimal management of DM and early detection of DM complications in those 
living with DM. In this study, we noticed a higher prevalence of DR in DM patients living in rural China 
than that in those living in urban areas. This urban-rural disparity of DR prevalence in people with DM 
is in line with the study by Liu and colleagues [22]. In the Chinese context, awareness (a history of phy-
sician-diagnosed), treatment (proportion of individuals taking diabetes medications), and control (the 
proportion of individuals with an HbA1c concentration of less than 7.0%) of DM among rural dwellers 
are all lower than that in urban dwellers, partly due to lower economic development level and restricted 
primary health resources in rural China [23,51,57]. The delayed diagnosis and non-optimal management 
of DM might be the primary causes of a higher prevalence of DR in rural China, but still need further 
confirmation in future studies.
Good glycemic control has long been recognized as one important factor for reducing vascular compli-
cations of DM, and it is also important in the prevention of DR [16,58]. In this study, higher levels of FBG 
and HbA1c have both been suggested as risk factors for DR in people with DM, which is in line with 
many previous investigations and synthesized results [56,59]. In addition, insulin treatment was identi-
fied to be with a higher odds of DR in DM patients according to our meta-analysis. Herein insulin treat-
ment should not be simply concluded as a “bad treatment” which directly causes DR. In previous studies, 
it was suggested that a larger proportion of participants using insulin therapy were those with T1DM or 
with longer-duration of DM, and people with DR may have already been preferentially treated with insu-
lin therapy [56,60,61]. In previous studies, higher SBP has been suggested as a risk factor for DR [2,58]. 
However, our meta-analysis of risk factors for DR only showed a slightly significant association between 
elevated SBP and DR. Given the effect of SBP on DR was only assessed based on five individual studies 
in our synthesized analysis, the lack of sufficient evidence logically calls for an updated analysis to better 
understand the role of SBP in the development of DR with new data coming in.
The increasing burden of DR might bring a higher pressure on available infrastructure and resources. Ide-
ally, periodic eye examinations should be conducted by all patients with DM. Regular follow-up to detect 
significant retinopathy, together with prompt interventions when necessary, is believed to be the most ef-
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fective method to reduce potential DR-related visual disabilities [1,3,62]. In China, screening of DR has 
not been well established into the primary health care system, and the need for adequate DR eye care re-
mains largely unaddressed [63,64]. Generally, DR screening could be evaluated in office or through tele-
medicine, and the latter has been suggested to be accurate and more cost-effective [65-67]. Furthermore, 
with the development of technology, a wholly automated approach with the assistance of artificial intel-
ligence might be especially beneficial in under-developed areas. Even in established screening centres, 
those techniques also have a potential to substantially reduce the grading workload [68,69].
With new epidemiological investigations emerging, the results of this study should be updated in a time-
ly and regular manner. In addition, there remains a genuine need for prompting international standard-
ized DR classification systems in Chinese scientific society, to facilitate communication and comparison 
across the world.
CONCLUSIONS
To conclude, this contemporary systematic review and meta-analysis estimated the prevalence, risk fac-
tors and burden of DR in China. The results from this study revealed a substantial burden of DR in Chi-
na. Optimal screening of and interventions on DR should be implemented in the Chinese health system. 
Improved epidemiological studies on DR are still required to guide eye care programmes in China.
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